Latest market price
8.55
-1.13-11.67%
OverviewShort InterestFilings
SLSQT92SELLAS Life Sciences Group, Inc.·NASDAQ
8.55-11.67%
TA
Loading chart...
Signal & projected range
Gap down — mean-reversionHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
XERS-5.04%$10.17SRPT-1.61%$18.32MESO-4.09%$14.54TRVI+0.52%$13.63VIR-2.65%$11.00ABSI-12.94%$9.69FTRE-5.97%$20.02SEPN-1.82%$43.20
Snapshot
Index—P/E—EPS (ttm)-0.21Insider Own9.77%Shs Outstand201.95MPerf Week-16.12%
Market Cap1.95BForward P/E—EPS next Y-0.09Insider Trans0.00%Shs Float199.70MPerf Month-14.56%
Enterprise Value1.82BPEG—EPS next Q-0.05Short Float26.92%Perf Quarter-13.73%
Income-33.00MP/S—EPS this Y—Short Ratio8.54Perf Half Y96.35%
Sales0.00P/B14.16EPS next Y—ROA-22.33%Short Interest53.76MPerf YTD156.76%
Book/sh0.68P/C14.16EPS next 5Y—ROE-35.91%52W High15.88 -46.16%Perf Year365.38%
Cash/sh0.68P/FCF—EPS past 3/5Y—ROIC-25.45%52W Low1.39 515.11%Perf 3Y975.56%
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin0.00%Volatility10.58% 7.96%Perf 5Y11.01%
Dividend TTM—EV/Sales—EPS Y/Y TTM—Oper. Margin0.00%ATR (14)1.02Perf 10Y-99.90%
Dividend Ex-Date—Quick Ratio18.83Sales Y/Y TTM—Profit Margin0.00%RSI (14)38.66Recom2.00
Dividend Gr. 3/5Y—Current Ratio18.83EPS Q/Q28.57%SMA20-14.32%Beta2.71Target Price35.00
Payout0.00%Debt/Eq0.01Sales Q/Q—SMA50-20.38%Rel Volume0.92Prev Close9.68
Employees13LT Debt/Eq0.00EarningsNov 18SMA20012.92%Avg Volume6.67MPrice8.55
IPO DateMar 12, 2008Option/ShortYes / YesEPS/Sales Surpr.-11.11% —Net Debt/EBITDA—Volume6,106,123Change-11.67%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-12-26ReiteratedIndustrial Alliance Securities$25 → $35
Jul-06-26ReiteratedIndustrial Alliance Securities$10 → $25
Nov-15-22ReiteratedIndustrial Alliance Securities$8.00
Jun-28-22ReiteratedCantor FitzgeraldOverweight$6.00
Nov-15-19UpgradeMaxim GroupHold → Buy
Mar-19-18UpgradeMaxim GroupHold → Buy
Latest News· Times ET
Oct-28-26
Oct-28-2608:35AM
SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemiaglobenewswire.com
Oct-26-26
Oct-26-2608:00AM
Sellas Life Sciences: Too Many Survivors For Its Own Trial PlanSeekingAlpha
Oct-20-26
Oct-20-2612:07AM
SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 YearsYahoo
Oct-18-26
Oct-18-2602:21AM
SELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 11.2% – Here’s What Happeneddefenseworld.net
Oct-15-26
Oct-15-2603:00AM
SciBase's EIS Technology Selected as Primary Endpoint in NIH Skin Barrier Studygurufocus.com
Oct-14-26
Oct-14-2604:24AM
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For DealsYahoo
Oct-07-26
Oct-07-2611:54PM
SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal HopesYahoo
Oct-06-26
Oct-06-2605:14PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSglobenewswire.com
Oct-01-26
Oct-01-2602:01AM
SLS Stock Snaps 3-Quarter Winning Streak — Retail Traders Speculate On Buyout, Eye Lease Through 2027Yahoo
Sep-29-26
Sep-29-2605:46PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSglobenewswire.com
Sep-25-26
Sep-25-2601:00PM
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancerglobenewswire.com
Sep-24-26
Sep-24-2605:34PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSprnewswire.com
12:59AM
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next TrialYahoo
Sep-17-26
Sep-17-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSprnewswire.com
03:21AM
This Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September RallyYahoo
Company

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
0000—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit
0000—————
Selling, General and Administrative Excl. Other15121214—————
Research and Development20161924—————
Other Operating Expense0010—————
Operating Income-35-28-32-38—————
Interest Expense
0000—————
Unusual Expense
—————————
Non-Operating Income (Expense)3111—————
Net Income Before Taxes-33-27-31-37—————
Income Taxes
0000—————
Consolidated Net Income-33-27-31-37—————
Net Income From Continuing Operations-33-27-31-37—————
Net Income-33-27-31-37—————
EPS (Recurring)-0.21-0.25-0.50-1.34—————
EPS (Basic, Before Extraordinaries)-0.21-0.25-0.50-1.34—————
EPS (Diluted)-0.21-0.25-0.50-1.34—————
EBITDA-26-2711—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
—————————
Gross Margin
—————————
Operating Margin
—————————
Net Margin
—————————
Shares Outstanding1891096128—————
Market Capitalization1,6164116330—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$17.57$13.00$8.43$3.85$-0.72● Close Price0.00K25.20K50.40K75.60K100.81KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kalin Katherine BachDirectorNov 19 '25Buy1.5963,400100,806104,400Nov 21
VAN NOSTRAND ROBERT LDirectorJun 12 '25Buy1.4810,00014,80020,400Jun 13
Wasman JaneDirectorMay 30 '25Buy1.6920,00033,80030,400Jun 02
Kalin Katherine BachDirectorMay 22 '25Buy1.8020,00036,00041,000May 22
Stergiou Angelos M.President and CEODec 05 '22Sale2.616,49416,938161,689Dec 05
Burns John ThomasSenior VP, Finance & CAODec 05 '22Sale2.591,1593,00229,347Dec 05
WOOD BARBARA AEVP, Gen. Counsel, Corp. Sec.Dec 05 '22Sale2.592,1535,57656,344Dec 05
Stergiou Angelos M.President and CEODec 02 '21Sale6.252,12013,252121,167Dec 03
WOOD BARBARA AEVP, Gen. Counsel, Corp. Sec.Dec 02 '21Sale6.258475,29842,028Dec 03
Burns John ThomasVP, Finance & Corp ControllerDec 02 '21Sale6.272311,44817,644Dec 03
Stergiou Angelos M.President and CEODec 31 '18Sale1.2523,27729,189426,858Jan 03
Nisi RudolphDirectorJun 20 '17Sale0.5550027314,864Jun 22
Hudson Bay Capital Management LP10% OwnerFeb 08 '17Sale0.842,363,4411,985,2902,036,559Feb 10
Hudson Bay Capital Management LP10% OwnerFeb 08 '17Buy1.001,1001,1000Feb 10
KRIEGSMAN STEVEN ADirectorJan 23 '14Sale5.92150,000888,5405,000Apr 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.